评估阿巴西普治疗难治性肾病综合征的随机临床试验设计
本文介绍了一项随机、安慰剂对照临床试验的设计,旨在评估阿巴西普对局灶节段性肾小球硬化或微小病变型肾病所致难治性肾病综合征的疗效。研究采用平行组与交叉设计的混合方案,主要终点为4个月内尿蛋白肌酐比降低≥50%且<3,计划样本量90例,有80%把握度检测28%的治疗差异。
要点
- 阿巴西普靶向CD80,可能恢复难治性肾病综合征的蛋白尿。
- 试验采用平行组与交叉混合设计,所有受试者均接受活性药物。
- 主要终点为4个月尿蛋白肌酐比降低≥50%且<3。
核心结论
- 该试验设计旨在验证CD80作为难治性肾病综合征治疗靶点,并采用基于精准医学的方法。
研究设计与样本
- 随机、安慰剂对照临床试验,采用平行组与交叉(转换)设计的混合方案。
- 对象为局灶节段性肾小球硬化或微小病变型肾病所致难治性肾病综合征患者。
- 每期治疗持续4个月,主要目标在第一期评估,次要目标利用两期数据评估。
- 所有受试者在其中一期接受活性药物。
- 计划样本量为90例患者。
主要发现
- 原文未报告试验结果,仅描述设计。
关键数值与推荐
- 主要结局为肾病范围蛋白尿改善至亚肾病范围,即基线至4个月尿蛋白肌酐比降低≥50%且水平<3。
- 计划样本量90例,有80%把握度检测28%的治疗差异。
临床怎么用
- 该设计为难治性肾病综合征的精准治疗试验提供框架,临床需等待试验结果验证。
局限性
- 原文未报告试验结果,仅为设计描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Treatment-resistant nephrotic syndrome is a rare form of glomerular disease that occurs in children and adults. No Food and Drug Administration-approved treatments consistently achieve remission of proteinuria and preservation of kidney function. CD80 (B7-1) can be expressed on injured podocytes, and administration of abatacept (modified CTLA4-Ig based on a natural ligand to CD80) has been associated with sustained normalization of urinary protein excretion and maintenance of glomerular filtration rate in experimental and clinical settings. METHODS: In this report, we describe the rationale for and design of a randomized, placebo-controlled, clinical trial of abatacept in patients with treatment-resistant nephrotic syndrome caused by focal segmental glomerulosclerosis or minimal change disease. The design is a hybrid of a parallel-group and crossover design (switchover) with the primary objectives assessed in the first period of the study and the secondary objectives assessed using data from both periods. All participants will receive the active agent in 1 of the periods. The duration of treatment will be 4 months per period. RESULTS: The primary outcome will be improvement in nephrotic-range proteinuria to subnephrotic range, that is, reduction from baseline to 4 months in urine protein:creatinine ratio ≥ 50% and to a level < 3. The projected sample size is 90 patients, which has 80% power to detect a treatment difference of 28%. CONCLUSION: This study advances efforts to validate CD80 as a therapeutic target for treatment-resistant nephrotic syndrome, and implements a precision medicine-based approach to this serious kidney condition in which the selection of a therapeutic agent is guided by the underlying disease mechanism operating in individual patients.
引用
- Trachtman H, Gipson DS, Somers M, et al. Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome. Kidney Int Rep. 2017. PMID: 29340321. doi:10.1016/j.ekir.2017.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。